Globe Newswire
Leading toy manufacturer introduces official fidget-trading playmat and licensed toy collection inspired by Mrs. Bench’s signature style and community
VALENCIA, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- World Tech Toys, a leading toy company known for trend-forward products, has partnered with viral TikTok creator Mrs. Bench as her master toy partner for its MOJIS brand. The deal was brokered by Blitz Licensing on behalf of World Tech Toys. The collaboration will... (continue reading...)
DASSAULT AVIATION
French corporation (société anonyme) with a share capital of 61,754,887.20 euros Headquarters: 78, quai Marcel Dassault 92210 SAINT-CLOUD 712 042 456 RCS Nanterre
Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers)
DateTotal number... (continue reading...)VALENCIA, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- World Tech Toys, a leading toy company known for trend-forward products, has partnered with viral TikTok creator Mrs. Bench as her master toy partner for its MOJIS brand. The deal was brokered by Blitz Licensing on behalf of World Tech Toys. The collaboration will introduce a collection of Mrs. Bench-inspired toys that capture the excitement of fidget collecting, trading and playing, bringing her popular social media... (continue reading...)
New industry analysis shows Excess & Surplus lines direct premium growth moderating after years of record expansion, while underwriting profitability and insurer financial strength remain strong
ROCKY HILL, Conn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- ALIRT Insurance Research recently released its annual U.S. Surplus Lines Overview, which examines industrywide trends and the financial performance of ALIRT's 50 Company E&S Lines Composite, highlighting the effects of... (continue reading...)
- Three iadademstat abstracts have been accepted for presentation
- Updated data from the ongoing Phase Ib ALICE-2 trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 95% overall response rate, 84% composite complete remission (CRc) rate and 74% CR rate; updated ALICE-2 data following completion of enrollment to be presented at the meeting
- Topline results from the Phase Ib FRIDA trial of iadademstat in combination with... (continue reading...)
More Globe Newswire
View Older Stories-
Ontario Federation of Labour endorses call for federal apology for Canada's role in enslavement of Africans
-
Students on Ice Foundation Opens Global Youth Applications for 2027 Expedition Season
-
Vaisala Xweather unveils Met-in-a-box, bringing world-class AI weather forecasting to every corner of the globe
-
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
-
Vaisala Xweather unveils Met-in-a-box, bringing world-class AI weather forecasting to every corner of the globe
-
KingSong Introduces F16 AVEN With Modular Design and Quick Release Motor Access
-
Attain enhances the power of purchase data across Amazon Ads DVA+ with direct audience integration
-
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
-
SKYX Announces That, Based on Growing Winter Demand, It Will Launch 4 New Plug & Play Turbo Heater Fan Models in 5 Different Colors
-
Applied Biologics Announces Full Enrollment of BIOxHEAL™ Phase 3 Sentinel Safety Cohort
-
October 2026 WOW Supply Chain Activity Index Holds at 43.4 as Warehouse Space Tightens Heading Into Peak Season
-
MEGL Secures US$100 Million Dedicated Credit Facility to Accelerate Cross-Border Timber Trading
-
RedCloud to Participate in the 15th Annual ROTH Technology Conference
-
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
-
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
-
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
-
Superior Energy Services Announces $650 Million Senior Unsecured Notes Offering
-
Sensolus Supply Chain Velocity Index: 1 in 3 Industrial Assets Sat Still for an Entire Month
-
Aggreko Introduces New Line of Battery Energy Storage Systems for Immediate and Large-Scale Applications
-
Harsco Rail Executes Agreement to Exit Deutsche Bahn Engineered-to-Order Contract and Receives Initial Payment from Sale of Project Assets to GBM
-
Feedonomics Now Available in Amazon’s Shop Direct Merchant Workspace, Making it Easier for Brands to Get Their Products in Front of Amazon Customers
-
Report: 86% of Insurance Executives in Canada Believe AI Will Strengthen Customer Trust, Only 33% of Policyholders Agree
-
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
-
Doba Adds $20 Cash Bonus to Referral Program for Ecommerce Marketers
-
Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
-
SoundHound AI and Ultraviolette Announce Major Expansion of Agentic Voice AI Across Global Electric Vehicle Lineup
-
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
-
Circana Launches Concept Testing and Forecasting Solutions to Help Brands Identify Winning Product Ideas and Predict Sales Potential
-
Tangram Announces Oral Presentation of TGM-148 Preclinical Data Highlighting Context-Dependent Mechanism of Action at the American Society of Hematology (ASH) 2026 Annual Meeting
-
Komodor Survey Finds More Than 50% of Engineering Organizations Face Control and Governance Issues as They Scale Agentic Operations
-
Formica Corporation Expands Design Possibilities with New Everform® Solid Surface and Homapal® Decors
-
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
-
Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting
-
TestGrid Launches TestGrid ONE, the AI Operating System That Runs Quality Engineering
-
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
-
Northrop Grumman to Participate in the Baird 2026 Global Industrial Conference
-
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
-
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
-
Secura Bio Announces Two Duvelisib Presentations on Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma at the 2026 American Society of Hematology Annual Meeting
-
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hem
-
Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting
-
TranscendAP and Carahsoft Partner to Expand Access to AI-Powered AP Automation Across the Public Sector
-
Sophos Helps Organizations Secure the AI-Era Network as Demands on Performance and Protection Grow
-
Jack's Got Your Back: Jackery Kicks Off Black Friday Early with up to $3,230 Off Home Backup Power Solutions
-
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory L
-
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
-
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
-
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
-
Atavistik Bio to Highlight Momentum Across Hematology Pipeline with Harmony-HHT Clinical Trial Update and New Preclinical Data from HHT and JAK2 V617F Programs at ASH 2026
-
New Study Finds Nearly Half of Women Seeking Help for Menstrual Symptoms Say Their Concerns Were Dismissed
